GRFS实时信号 | 通过Getagraph.com最大化利润

购买 107641 min ago

@ $8.53

发出时间: 15 Feb 2024 @ 00:16

回报率: -25.21%

上一信号: Feb 14 - 01:31

上一信号: 出售

回报率: 1.67 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	673 447
平均成交量	2.15M
市值	5.42B
EPS	$0.140 ( 2024-03-05 )
Last Dividend	$0.456 ( 2021-06-03 )
Next Dividend	$0 ( N/A )
P/E	63.80
ATR14	$0.00700 (0.11%)

音量相关性

長: -0.07 (neutral)

短: -0.05 (neutral)

Signal:(39.858) Neutral

Grifols S.A. 相关性

10 最正相关
NETE	0.949
MMAC	0.937
TKNO	0.911
STRA	0.907
AMRB	0.897
VTRS	0.891
WLDN	0.89
TRUE	0.889
GRAB	0.887
HOLX	0.885

10 最负相关
SVAC	-0.951
PAIC	-0.935
RMRM	-0.93
SVOK	-0.91
TLGT	-0.906
MTSL	-0.873
CNET	-0.865
FTOC	-0.861
FVE	-0.857
FEYE	-0.854

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Grifols S.A. 相关性 - 货币/商品

0.44
( neutral )

0.30
( neutral )

0.00
( neutral )

0.67
( moderate )

0.06
( neutral )

Grifols S.A. 财务报表

Annual	2023
营收:	$6.59B
毛利润:	$2.32B (35.24 %)
EPS:	$0.0873

FY	2023
营收:	$6.59B
毛利润:	$2.32B (35.24 %)
EPS:	$0.0873

FY	2022
营收:	$6.06B
毛利润:	$2.23B (36.80 %)
EPS:	$0.310

FY	2021
营收:	$4.93B
毛利润:	$1.96B (39.78 %)
EPS:	$0.270

Financial Reports:

No articles found.

Grifols S.A. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Grifols S.A. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 5.88 - average (63.08%) | Divividend Growth Potential Score: 1.372 - No dividend growth expected in the near future

Information

First Dividend	$0.00650	2013-05-29
Last Dividend	$0.456	2021-06-03
Next Dividend	$0	N/A
Payout Date	2021-06-14
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	$3.04	--
Avg. Dividend % Per Year	0.38%	--
Score	1.9	--
Div. Sustainability Score	5.88
Div.Growth Potential Score	1.372
Div. Directional Score	3.63	--

Next Divdend (Est)
(2024-08-26)

$0 Estimate 0.00 %

Dividend Stability

0.07 Very Bad

Dividend Score

1.90

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2013	$0.136	1.06%
2014	$0.301	1.72%
2015	$0.353	2.05%
2016	$0.350	2.19%
2017	$0.375	2.33%
2018	$0.479	2.05%
2019	$0.394	2.18%
2020	$0.201	0.85%
2021	$0.456	2.41%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0251	1.500	9.50	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00769	1.200	9.74	10.00	[0 - 0.3]
returnOnEquityTTM	0.0279	1.500	-0.801	-1.202	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.79	0.800	1.069	0.855	[1 - 3]
quickRatioTTM	0.629	0.800	-1.006	-0.805	[0.8 - 2.5]
cashRatioTTM	0.229	1.500	9.84	10.00	[0.2 - 2]
debtRatioTTM	0.425	-1.500	2.92	-4.38	[0 - 0.6]
interestCoverageTTM	2.33	1.000	-0.248	-0.248	[3 - 30]
operatingCashFlowPerShareTTM	0.307	2.00	9.90	10.00	[0 - 30]
freeCashFlowPerShareTTM	-0.0538	2.00	-0.0269	-0.0538	[0 - 20]
debtEquityRatioTTM	1.564	-1.500	3.74	-5.62	[0 - 2.5]
grossProfitMarginTTM	0.381	1.000	6.99	6.99	[0.2 - 0.8]
operatingProfitMarginTTM	0.135	1.000	9.30	9.30	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.0229	1.000	-0.984	-0.984	[0.2 - 2]
assetTurnoverTTM	0.306	0.800	-1.291	-1.033	[0.5 - 2]
Total Score				5.88

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.48	1.000	7.63	0	[1 - 100]
returnOnEquityTTM	0.0279	2.50	-0.515	-1.202	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.0538	2.00	-0.0179	-0.0538	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.307	2.00	9.90	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.413	1.500	-0.582	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0317	1.000	-1.708	0	[0.1 - 0.5]
Total Score				1.372

Grifols S.A.

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.